6-7 NEWS
Matt Hancock unveils new National Institute for Health Protection; FDA approves Novartis' Kesimpta

8-11 CORONAVIRUS NEWS
Moderna's COVID-19 vaccine shows promise in older adults; WHO director-general warns against vaccine nationalism

12 DARWIN'S MEDICINE
You might think better if you were less of a scientist

13 POLICY AND PUBLIC HEALTH
The important lessons learned from COVID-19 in the Americas

14 DIVERSITY AND INCLUSION
It may not be something we can change overnight, but it is certainly something we need to start to address now

15 WHAT MAKES A GREAT LAUNCH
LEADER AND LAUNCH TEAM?
Building frameworks, processes and tools to help bring some structure to the launch process

16-17 COVID-19 AND ANTIMICROBIAL RESISTANCE
Why antimicrobial resistance needs to be
addressed with the same urgency as COVID-19

18-20 SURVIVING CANCER – A NEW ERA FOR PATIENTS
Now more than ever, a shift in perspective
is needed – from seeing cancer as an intense battle that is either won or lost, to viewing it as a condition that, given the right treatment, can potentially be managed over time

22-23 SWITZERLAND – A LIFE SCIENCES HUB
A rich diversity of pharma and biotech companies sustain activity and help
maintain its reputation as a highly innovative country

26-27 MULTILINGUAL REMOTE CONFERENCING
Turning the pharmaceutical language behind vaccine development into engaging, accessible content

30-32 EMPLOYEE ENGAGEMENT
Route 66: can remote working put two-thirds of us back on the road to engaged employment?

34-35 A HOLISTIC APPROACH TO PATIENT CARE
The importance of recognising patients as individuals

36-37 FORMULARY INTELLIGENCE
Could formulary intelligence be your brand differentiator?

38-39 BRAND STRATEGY
The importance of pharma intelligence
in setting brand strategy

40-41 LEADERSHIP AND TALENT
Investing in unique leadership development

45 HEALTHCARE COMMS
Porterhhouse Medical Group joins imc; Cello
Health to be acquired by Arsenal Capital Partners

46 PEOPLE
Q&A with Isabel Gibson

September 2020